Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis

Background and Objective: The association of non-alcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD) with intensive care unit (ICU) admissions and the need for mechanical ventilation and disease severity in COVID-19 patients. Material and Methods: A systematic literature review was conducted on the databases: Cochrane, Embase, PubMed, ScienceDirect, and the Web of Science from January 2019 to June 2022. Studies evaluating MAFLD using laboratory methods, non-invasive imaging, or liver biopsy were included. The study protocol was registered in PROSPERO (ID CRD42022313259), and PRISMA guidelines were followed. The NIH quality assessment tool was used for quality assessment. RevMan version 5.3 software was used for pooled analysis. A sensitivity analysis was performed to assess the result’s stability. Results: A total of 37,974 patients from 17 studies were assessed for the association between MAFLD and ICU admission. A total of 3396 COVID-19 patients required ICU admission: 1236 (20.41%) in the MAFLD group and 2160 (6.77%) in the non-MAFLD group. The odds ratio was 1.86 for ICU admission, p = 0.007, and a (95% CI) of [1.18–2.91]. A total of 37,166 patients from 13 studies were included in the need for invasive mechanical ventilation analysis. A total of 1676 patients required mechanical ventilation: 805 in the MAFLD group (14.20% of all MAFLD patients) and 871 patients in the non-MAFLD group (2.76% of all non-MAFLD patients). The odds ratio was 2.05, p = 0.02, and a (95% CI) of [1.12–3.74]. A total of 5286 patients from 14 studies were included in the COVID-19 disease severity analysis. Severe COVID-19 was seen in 1623 patients, with 33.17% (901/2716) of MAFLD patients and 28.09% (722/2570) of non-MAFLD patients having severe disease. The odds ratio was 1.59 for disease severity, p = 0.010, and a (95% CI) of [1.12–2.26]. Conclusions: Our meta-analysis suggests that there are significantly increased odds of ICU admissions, a need for invasive mechanical ventilation, and disease severity in MAFLD patients who acquire COVID-19.

[1]  R. Kashyap,et al.  Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis , 2023, World journal of gastroenterology.

[2]  Xiaoli Ma,et al.  Comprehensive Analysis of N6-Methyladenosine (m6A) RNA Methylation Regulators and Tumour Microenvironment Cell Infiltration Involving Prognosis and Immunotherapy in Gastroesophageal Adenocarcinomas , 2022, Canadian journal of gastroenterology & hepatology.

[3]  U. Hayat,et al.  The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis , 2022, Kansas journal of medicine.

[4]  S. Ozturk,et al.  Prevalence and Prognostic Importance of High Fibrosis-4 Index in COVID-19 Patients , 2022, International journal of clinical practice.

[5]  Jinkwon Kim,et al.  Association between the fatty liver index and the risk of severe complications in COVID-19 patients: a nationwide retrospective cohort study , 2022, BMC Infectious Diseases.

[6]  K. Madan,et al.  Is Fatty Liver Associated with Increased Mortality and Morbidity in Coronavirus Disease 2019 (COVID-19) Pneumonia? , 2022, Journal of Clinical and Experimental Hepatology.

[7]  A. Vince,et al.  Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study , 2022, Open forum infectious diseases.

[8]  D. Kershenobich-Stalnikowitz,et al.  NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study , 2022, Internal and Emergency Medicine.

[9]  D. Mutter,et al.  Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19 , 2022, Clinics and Research in Hepatology and Gastroenterology.

[10]  Yongli Zheng,et al.  Not Only High Number and Specific Comorbidities but Also Age Are Closely Related to Progression and Poor Prognosis in Patients With COVID-19 , 2022, Frontiers in Medicine.

[11]  S. Kashyap,et al.  Impact of Metabolic Syndrome on Severity of COVID-19 Illness. , 2022, Metabolic syndrome and related disorders.

[12]  M. Iftikhar,et al.  Outcomes of Nonalcoholic Fatty Liver Disease In Covid Positive Diabetic Patients: Cross Sectional Study , 2021, Pakistan Journal of Medical & Health Sciences.

[13]  Guo-bao Wu,et al.  Association between non‐alcoholic fatty liver disease with the susceptibility and outcome of COVID‐19: A retrospective study , 2021, Journal of cellular and molecular medicine.

[14]  A. Koyanagi,et al.  Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort , 2021, Journal of Korean medical science.

[15]  L. Gerber,et al.  Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection , 2021, Hepatology communications.

[16]  Jian Wang,et al.  Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores , 2021, Journal of clinical laboratory analysis.

[17]  L. Tamariz,et al.  Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease , 2021, Surgery for Obesity and Related Diseases.

[18]  Zachary P. Fricker,et al.  Radiographic Hepatic Steatosis Is Not Associated With Key Clinical Outcomes Among Patients Hospitalized With COVID-19 , 2021, Gastroenterology research.

[19]  M. Balakrishnan,et al.  Global Epidemiology of Chronic Liver Disease , 2021, Clinical liver disease.

[20]  C. Fierbinţeanu-Braticevici,et al.  The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on COVID-19 Disease Prognosis , 2021, Medicina.

[21]  R. Pranata,et al.  Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis , 2021, European journal of gastroenterology & hepatology.

[22]  J. Mayerle,et al.  Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study , 2021, Gut.

[23]  A. Ciudin,et al.  The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19 , 2021, Therapeutic advances in gastroenterology.

[24]  Fateen Ata,et al.  NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues , 2020, Journal of Hepatology.

[25]  Yuanlin Song,et al.  COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms , 2020, Signal Transduction and Targeted Therapy.

[26]  M. Thursz,et al.  In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19 , 2020, PloS one.

[27]  J. A. Cook,et al.  Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study , 2020, Journal of Hepatology.

[28]  Chia-Yang Hsu,et al.  Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19 , 2020, Digestive Diseases and Sciences.

[29]  A. Branch,et al.  Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study , 2020, Clinical Gastroenterology and Hepatology.

[30]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[31]  A. Mari,et al.  Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study , 2020, European journal of gastroenterology & hepatology.

[32]  Qianghu Wang,et al.  Implications of liver injury in risk-stratification and management of patients with COVID-19 , 2020, Hepatology International.

[33]  Jian Wang,et al.  Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease , 2020, Hepatology communications.

[34]  Yangang Wang,et al.  Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[35]  P. Hegyi,et al.  Obesity is a risk factor for developing critical condition in COVID‐19 patients: A systematic review and meta‐analysis , 2020, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[36]  B. Hamm,et al.  The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany , 2020, Metabolism.

[37]  V. Wong,et al.  Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19 , 2020, Gut.

[38]  H. Tilg,et al.  Liver stiffness by transient elastography accompanies illness severity in COVID-19 , 2020, BMJ open gastroenterology.

[39]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.

[40]  D. Wong,et al.  Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[41]  M. Zheng,et al.  Metabolic‐associated fatty liver disease is associated with severity of COVID‐19 , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[42]  Roger Williams,et al.  Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis? , 2020, Journal of Hepatology.

[43]  Ashish Kumar,et al.  Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19 , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[44]  H. Tilg,et al.  From NAFLD to MAFLD: when pathophysiology succeeds , 2020, Nature Reviews Gastroenterology & Hepatology.

[45]  Feng Gao,et al.  Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients. , 2020, Journal of gastroenterology and hepatology.

[46]  M. Zheng,et al.  Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores , 2020, Gut.

[47]  Sittichai Tantipasawasin Coronavirus disease (COVID-19) Pandemic , 2020 .

[48]  M. Zheng,et al.  Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis , 2020, Journal of Hepatology.

[49]  Yizhen Chen,et al.  Guidelines for the diagnosis and treatment of coronavirus disease 2019 (COVID-19) in China. , 2020, Global health & medicine.

[50]  C. Rentsch,et al.  Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54–75 Years , 2020, medRxiv.

[51]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[52]  Jing Xu,et al.  Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study , 2020, Journal of Hepatology.

[53]  L. Luzi,et al.  Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic , 2020, Acta Diabetologica.

[54]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[55]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[56]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[57]  Douglas G. Altman,et al.  Analysing data and undertaking meta‐analyses , 2019, Cochrane Handbook for Systematic Reviews of Interventions.

[58]  M. Page,et al.  Considering bias and conflicts of interest among the included studies , 2019, Cochrane Handbook for Systematic Reviews of Interventions.

[59]  F. Tacke,et al.  Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism , 2019, JHEP reports : innovation in hepatology.

[60]  A. Charlett,et al.  Study quality assessment tools , 2016 .

[61]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[62]  Michele Tarsilla Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[63]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. , 2008, Cleveland Clinic journal of medicine.

[64]  Douglas G. Altman,et al.  Chapter 9: Analysing Data and Undertaking Meta-Analyses , 2008 .

[65]  E. Reyes,et al.  Association of nafld and mafld with mortality in patients hospitalized with COVID-19 infection , 2021 .